April 14th 2025
Vitrakvi (larotrectinib) was first granted accelerated approval by FDA in November 2018.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Are Disposable Components Powerful Enough to Manufacture Highly Potent Drugs?
August 18th 2010Making highly potent active pharmaceutical ingredients (HPAPIs) can be costly because the process often requires equipment specialized to achieve containment and extra attention to safety concerns. Pharmaceutical professionals may wonder whether disposable components, which have reduced the cost of some operations, might be appropriate in the manufacture of HPAPIs.
Senate Introduces New Bill on Drug-Manufacturing Quality Standards
August 12th 2010Sen. Michael Bennet (D-CO) introduced a bill earlier this month, the Drug Safety and Accountability Act of 2010, which is designed to improve regulatory oversight of drug-manufacturing facilities and improve related quality standards and monitoring.
FDA Recommends Reducing Residual Drug in Transdermal Delivery Systems
August 5th 2010In a draft guidance published this week, the US Food and Drug Administration recommended that makers of transdermal and transmucosal drug-delivery systems use "an appropriate scientific approach" during product design, development, and manufacturing to minimize the amount of residual drug substance present at the end of the products' labeled use periods.
Green Drug Delivery: Spray-dried solid amorphous dispersions with a cellulosic exicpient
August 2nd 2010Green chemistry in pharmaceutical development often centers around approaches in the synthesis of the active ingredient, but green-chemistry techniques also can be applied to drug-product manufacturing, formulation development, and drug delivery.
Merck KGaA Acquires Millipore and Founds New Divisions
July 22nd 2010Merck KGaA (Darmstadt, Germany), a global pharmaceutical and chemical company, completed its acquisition of Millipore (Billerica, MA), a life-science company, last Thursday for an aggregate purchase price of roughly EUR 5.2 billion ($6.7 billion).
Drug Industry Criticizes Patent Settlement Provisions in House Spending Bill
July 8th 2010The US House of Representatives passed on July 1, 2010, HR 4899, the Supplemental Appropriations Act of 2010, which included provisions restricting patent settlements between innovator-drug and generic-drug companies, a move that drew criticism from both sectors of the pharmaceutical industry.